Local researchers are seeking patients of all ages with severe renal (kidney) impairment due to primary hyperoxaluria (PH) for a clinical trial.
You may be interested in the PHYOX™ clinical trial program, a series of research studies evaluating a new investigational medicine called nedosiran, formerly DCR-PHXC, for the treatment of patients with PH.
For more information on the trial, visit clinicaltrials.gov and enter the identifier number NCT04580420, or click on the following link: https://clinicaltrials.gov/
Residents of the EU can visit EudraCT and enter the identifier number 2020-002826-97.
See if You or a Loved One Qualifies!
To participate in the PHYOX7 study, patients must:
- Have been diagnosed with PH by a physician, confirmed by genotyping
- Have severe renal impairment
- Have no history of systemic oxalosis
- Either have no history, or a history of 18 months or less receiving dialysis
If you or someone you love has PH and you would like to learn more about the PHYOX™ clinical trials, fill out the form below.
A study representative will contact you and answer any questions you may have. Your information will only be used for the purpose of this study, unless authorized otherwise.
What to Expect
Potential patients will be screened over a period lasting no longer than 6 weeks. Qualified patients will be enrolled into the study.
Patients will receive monthly doses of nedosiran over the course of 42 months. The first 6 months are known as the primary treatment period. Upon successful completion of this period including the Day 180 visit, participants will continue for 3 years or until nedosiran is commercially available, whichever comes first.
About Primary Hyperoxaluria
Primary hyperoxaluria (PH) is a family of severe, ultra-rare, genetic liver disorders characterized by the overproduction of oxalate, a natural chemical in the body that is normally eliminated as waste through the kidneys. For more information on PH, click here.
About Dicerna
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, is focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Between Dicerna and our collaborative partners, we currently have more than 20 active discovery, preclinical or clinical programs focused on cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain.
For more information on Dicerna’s Privacy Policy, click here.
Safety Information
Nedosiran, formerly DCR-PHXC, is an investigational drug intended for the treatment of patients with PH. Investigational drugs are medicines that have not yet been approved by appropriate regulatory agencies. The safety and efficacy for nedosiran has not been established yet. Current and future studies are evaluating the safety and efficacy for nedosiran.
©2021 Dicerna Pharmaceuticals, Inc. / Lexington, MA
English
Français
Deutsch
Español